A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsUpdate on the Diagnosis and Treatment of Cholangiocarcinoma.The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.New Horizons for Precision Medicine in Biliary Tract Cancers.Novel investigational therapies for treating biliary tract carcinoma.Intrahepatic cholangiocarcinoma: current management and emerging therapies.Emerging molecular therapeutic targets for cholangiocarcinoma.Current biologics for treatment of biliary tract cancers.SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line settingErratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 studyCholangiocarcinoma - evolving concepts and therapeutic strategies.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.New molecular and immunotherapeutic approaches in biliary cancer.MEK inhibitors for the treatment of NRAS mutant melanoma
P2860
Q26751224-270A03F2-E6DD-4D1F-AAB5-37CD6A2AFD1EQ30238895-689D302C-2B55-4B3B-83CB-0FE162FFC76FQ33656860-BCE5EA70-AF43-43B9-93EF-D91BC25D0983Q37691482-27FC05AE-2217-4798-AC81-425083AA7F5EQ38619219-43E7C759-A91A-4951-990D-A212E7F647CEQ38799963-01939991-8D41-4555-A333-82FBE05E9FD9Q39186928-4BC5A395-6858-4D1B-8207-EBF241B068A2Q39227356-C7B0A522-2E23-4C96-8029-1AB8236C5699Q39453572-8678CE69-3B9F-49D1-8D85-4CAEA0508552Q42275107-C8E0132D-5269-45FC-95C2-844CE59B819FQ42575504-A68A00A3-6F9A-44EC-B710-7F465CC65345Q46087686-14D86624-6433-4BAF-838D-D6F39A7CEA07Q47429093-6016A458-3A1A-4AC0-BCE3-AC1F7574EC2EQ54476966-4A7DCBDC-840D-42B3-A23E-49049B19E65BQ56889985-A2F757D8-6394-4B5B-B0E6-FCC9E5D6A8AA
P2860
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A phase 1b study of Selumetini ...... ract cancer: the ABC-04 study.
@ast
A phase 1b study of Selumetini ...... ract cancer: the ABC-04 study.
@en
type
label
A phase 1b study of Selumetini ...... ract cancer: the ABC-04 study.
@ast
A phase 1b study of Selumetini ...... ract cancer: the ABC-04 study.
@en
prefLabel
A phase 1b study of Selumetini ...... ract cancer: the ABC-04 study.
@ast
A phase 1b study of Selumetini ...... ract cancer: the ABC-04 study.
@en
P2093
P2860
P1433
P1476
A phase 1b study of Selumetini ...... ract cancer: the ABC-04 study.
@en
P2093
Ajithkumar Sukumaran
Andre Lopes
Delyth McEntee
Dymphna Lee
Harpreet Wasan
John Bridgewater
Juan W Valle
Maravic Ricamara
Marian Duggan
Sandra Beare
P2860
P2888
P356
10.1186/S12885-016-2174-8
P407
P577
2016-02-24T00:00:00Z
P5875
P6179
1000876345